ORIC Pharmaceuticals, Inc. (ORIC)
$11.31-4.23%Close
SELLBEAR · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.2B
- Beta
- 0.98
- P/E (TTM)
- -8.38
- Short % float
- 33.50%
- Days to cover
- 9.8
- SI change
- -6.9%
- 1W
- -5.59%
- 1M
- -10.59%
- vs SPY 1W
- -5.45%
- vs SPY 1M
- -13.10%
Industry peers
FMP comparable companies · ranked by market cap
- ELVNSELLEnliven Therapeutics, Inc.$2.9BCRISISQ 11$40.84-3.31%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$4.90-3.67%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 15$16.55-15.71%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 4$19.60-5.31%
- JANXBUYJanux Therapeutics, Inc.$1.1BRECOVERYQ 11$18.15-5.34%
- CRVSSELLCorvus Pharmaceuticals, Inc.$845MCRISISQ 12$10.05-6.37%
- AVBPSELLArriVent BioPharma, Inc.$767MCRISISQ -6$16.46-2.25%
- VSTMBUYVerastem, Inc.$725MRECOVERYQ 4$8.25-9.70%
- NVCTSELLNuvectis Pharma, Inc.$523MCRISISQ 37$19.69-7.82%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 16
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-21.2%
REV YoY-
ROE-35.4%
EPS YoY-
ROA-34.7%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-8.38
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B3.20
P/FCF-
EV/EBITDA-7.95
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.87
ALTMAN Z-
CURR RATIO13.19
ND/EBITDA-
BETA0.98
Company news
FAQ
- What is LOPJLB’s current signal on ORIC?
- LOPJLB’s latest quantitative signal on ORIC Pharmaceuticals, Inc. (ORIC) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is ORIC in?
- ORIC Pharmaceuticals, Inc. (ORIC) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does ORIC Pharmaceuticals, Inc. (ORIC) do?
- ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another cand…